Mission of AABC

The mission of Alzheimer’s Association Business Consortium (AABC) is to advance Alzheimer’s disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer’s research and the goals of its member organizations. They provide leadership and direction to the group’s areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new members who are aligned in their commitment to research and innovation. To express interest in joining, please email Dr. Leen Kawas (kawas@m3bio.com), co-chair; Dr. Judy Walker (jwalker@cerecin.com), co-chair; or Dr. Rebecca Edelmayer (rmedelmayer@alz.org), facilitator.

Welcome New Members

AABC is growing! Welcome to:

- **Tom Sawyer – Cognetivity Neurosciences**
  Cognetivity Neurosciences has created a rapid, diagnostic cognitive assessment test that uses artificial intelligence to interpret results. [Read more](#).

News from AABC members and growth AD companies

**712 North Inc. Joins the QB3 Garage @ Berkeley**

712 North Inc. announced it has joined the QB3 Garage @ Berkeley in July 2019. 712 North is an early-stage therapeutics company developing personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases. Supported by a phase I SBIR grant from the National Institute on Aging (NIA), the team around the founder Dr. Marcel V. Alavi will pursue a discovery program together with the Small Molecule Discovery Center at UCSF. “Our new lab on the UC Berkeley campus is awesome because it is really close to all our collaborators at UCSF and the Molecular Foundry at the Lawrence Berkeley National Laboratory,” says Dr. Alavi. QB3 is a life science accelerator created in 2000 by the University of California to support innovation and entrepreneurship. QB3 offers incubator space at six different sites across the San Francisco Bay Area and at Santa Cruz. For more information please visit: [www.712north.com](http://www.712north.com)
**Athira Pharma’s Leen Kawas Selected as Young Leader by French-American Foundation**

Athira Pharma, Inc., a clinical-stage company dedicated to developing first-in-class therapies for Alzheimer’s and Parkinson’s that are focused on regeneration, today announced that Leen Kawas, President and CEO of Athira, has been selected as a member of the French-American Foundation’s 2019 class of Young Leaders.

The prestigious Young Leaders program, established by the Foundation in 1981, brings together a transatlantic group under the age of 40 from a vast array of sectors who share a passion for forging bonds in a globalized world and using their influence for the common good. During the two-year program, Young Leaders convene to discuss issues of common concern and meet with local and global specialists. Read more.

**Imaginostics CEO Gharagouzloo Receives memoryBLUE HUSTLE Award**

Imaginostics, Inc. is a Boston-based diagnostic imaging biotechnology company that is developing innovative quantitative vascular imaging biomarkers for the early detection of Alzheimer’s Disease and Related Dementia (ADRD). Imaginostics holds licensing rights to four patents, including the Quantitative Ultra-short Time-to-Echo Contrast-Enhanced (QUTE-CE) MRI technology (2015).

Codi A. Gharagouzloo, Ph.D., CEO, was recently featured in two expert panels on innovation in aging: at the April 11 MIT Enterprise Forum panel on Entrepreneurial Opportunities in the Longevity Economy, and the June 6 Harvard Catalyst Panel on Enabling Healthy Aging with Advanced Technologies. On June 12, Imaginostics was awarded the memoryBLUE HUSTLE Award for best pitch at the MIT Enterprise Forum Startup Spotlight. Read more.

This summer, Dr. Gharagouzloo is launching a new research project with Advisory Board member Dr. Peder Larson at the University of California, San Francisco (UCSF) to expand Imaginostics’ software suite towards the advancement of its quantitative imaging biomarkers.

**Lauren Sciences CEO Rosenbaum Invited Speaker at Brain Tumor Biotech Summit**

Lauren Sciences Founder, Chairman & CEO Susan Rosenbaum was an invited speaker on V-Smart® Nanomedicine for GBM at the “Novel Applications and Treatments for Malignant Glioma” session, Brain Tumor Biotech Summit.

**FDA Grants Breakthrough Device Designation to NeuraMetrix**

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the NeuraMetrix brain health monitoring solution. The designation is granted for devices “that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.” The approved use is monitoring of Parkinson’s disease (PD) to more effectively treat patients with PD, which is a significant challenge for neurologists today as they only see the patient a few times a year.

NeuraMetrix’s digital biomarker measures inconsistency of typing cadence (the rhythm of how we type on a keyboard), a proven indicator of brain health. Clinical data has demonstrated that NeuraMetrix may be effective for Central Nervous System (CNS) diseases such as PD, Alzheimer’s disease (AD) and Depression. Read more.

**Approval to market NeuraMetrix in Europe**

NeuraMetrix has received a Class I Monitoring CE Mark under the European Medical Device Directive so that NeuraMetrix can market its product on the European market.

**NeuraMetrix was a Finalist at Pitching Contests**

NeuraMetrix was a finalist for the $10K Business Plan Competition at the Silicon Valley Boomer Venture Summit. Read more.
Neuronscent Announces FDA Clearance of IND Application for NNI-362, an Aging Therapy to Treat Alzheimer’s Disease

Neuronscent Inc., a privately-held neuron regeneration therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its proprietary oral therapeutic, NNI-362, to proceed into Phase 1 clinical testing in a healthy aged population.

NNI-362, discovered by Neuronscent’s founder, is able to selectively stimulate the conversion of human brain neural progenitor cells to mature functioning neurons. This stimulation should reverse the cognitive and functional decline seen in aging Alzheimer’s disease (AD) patients.

Read more.

T3D Therapeutics to Receive $9 Million Multiyear National Institute on Aging Grant for Phase 2 PIONEER Study in Mild-to-Moderate Alzheimer’s Disease Patients

T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced that it has received a grant expected to total $9 million dollars over four years from the National Institute on Aging (NIA), part of NIH, to help fund a Phase 2 clinical study of T3D-959, a novel, metabolic-focused AD drug treatment.

The Phase 2 PIONEER study (Prospective therapy to Inhibit and Overcome Alzheimer’s Disease Neurodegeneration via Brain EnErgetics and Metabolism Restoration) is expected to initiate patient dosing in early 2020. PIONEER is a double-blind, placebo-controlled, parallel-group Phase 2 safety and efficacy study expected to enroll up to 252 adults with mild-to-moderate Alzheimer’s disease (MMSE 16-26). PIONEER will enroll subjects who will receive one of three different doses of T3D-959 or a placebo for 24 weeks. Read more.

Funding Opportunities

NIA’s Office of Small Business Research (SBIR) has significantly increased its funding and has a call for applications for numerous grants. The next deadline for submission is Sept. 5. Read more.

Upcoming Events

Alzheimer's Association International Conference® 2019 (AAIC®)
Los Angeles, California | July 12-18: Preconferences and Annual Conference Events

Congratulations to our member company that is presenting at AAIC. We encourage fellow members to support the following presentation:

Athira Pharma

Poster #33719
Therapeutics: Clinical
Date: Tuesday, July 16, 2019
Time: 9:30 a.m.-4:15 p.m.
Location: Los Angeles Convention Center, South Hall GH
Title: Phase 1 Study of Ndx-1017: Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Young and Elderly Volunteers
Presenting author: Xue Hua
Workshop: Commercializing a Novel Therapeutic Target for Alzheimer’s Disease
Date: Saturday, July 13
Time: 1-5 p.m.
Location: Los Angeles, CA

AAIC is hosting a preconference workshop (additional registration fee) that AABC members are encouraged to attend. This workshop will address key considerations and challenges when starting a new company. Read more.

AABC In-Person Meeting
Date: Monday, July 15
Time: Noon-1:30 p.m.
Location: JW Marriott, Georgia Room

ISTAART Member Reception
(You must be a member of ISTAART to attend)
Date: Monday, July 15
Time: 6-8 p.m.
Location: InterContinental LA Downtown Hotel, Hollywood Ballroom and Pool Deck

Past Events

Webinar: AABC Ask the Expert – CEO Panel
On April 25, AABC hosted a CEO panel that featured Kira Sheinerman, Ph.D., MBA, DiamiR; Charles Stacey, M.D., Cerecin; and Ken Moch, MBA, Cognition Therapeutics. The panelists discussed their experiences, challenges and best practices as CEOs of companies in diverse Alzheimer’s research and different stages of company development. Click here for the recording.

General Postings to AABC’s Membership
To help us grow AABC, please continue to introduce new members and/or companies to our group. We also welcome ideas for this newsletter — or events — so we can better serve you. Please send your suggestions to Dr. April Ross at aqross@alz.org.